SCLERODERMA DIAGNOSTIC PANEL (ANA, U1 SM RNP, CENTROMERE ABS, SCLERODERMA - 70 IGG) in Vasundhara, Ghaziabad

SCLERODERMA DIAGNOSTIC PANEL (ANA, U1 SM RNP, CENTROMERE ABS, SCLERODERMA - 70 IGG)

Test Overview

Scleroderma Diagnostic Panel (ANA, U1 SM RNP, Centromere Abs, Scleroderma-70 IgG): Price, Purpose, Range & Reports 
The Scleroderma Diagnostic Panel is a comprehensive and essential blood test used to aid in the diagnosis and classification of Scleroderma (Systemic Sclerosis, SSc), a chronic, rare autoimmune disease that causes thickening and fibrosis of the skin and internal organs. This panel bundles several key autoantibody tests, specifically ANA (Antinuclear Antibodies) screening, U1 SM RNP, Centromere Antibodies, and Scl-70 (Scleroderma-70) IgG, to determine the specific antibody profile associated with the patient’s condition.

Identifying these antibodies is crucial because they are highly predictive of the type of Scleroderma (Limited vs. Diffuse) and the potential risk of internal organ damage. If you are searching for a reliable Scleroderma Diagnostic Panel price or a comprehensive test near me, Apollo 24|7 provides convenient access to accredited testing services for complex rheumatology diagnostics, along with secure and timely report delivery.

What is the Scleroderma Diagnostic Panel?

The Scleroderma Diagnostic Panel is a blood test used to detect specific autoantibodies associated with systemic sclerosis (scleroderma), an autoimmune disease that affects the skin, blood vessels, and internal organs. This panel helps support diagnosis, classify the subtype of the disease, and assess the risk of organ involvement.

Key components of the panel typically include antinuclear antibodies (ANA), anti-centromere antibodies (ACA), anti-Scl-70 (topoisomerase I) antibodies, and U1 small nuclear ribonucleoprotein (U1-Sm RNP) antibodies. The presence and pattern of these antibodies provide valuable information about disease activity, prognosis, and potential overlap with other connective tissue disorders.

What is the Scleroderma Diagnostic Panel Price?

The cost of the Scleroderma Diagnostic Panel reflects its status as a specialised test that involves running and analysing multiple distinct, high-specificity immunoassays (such as ELISA or Immunoblot) in a single workflow.

Factors Affecting the Test Cost

The final price is influenced by these essential quality and service factors:

• Complexity of Assays: The panel requires separate reagents and sophisticated analysis for each antibody marker, which is more involved than a single general screening test.
• Specialised Interpretation: The value includes the laboratory expertise needed to correlate the ANA pattern with the specific antibody results for comprehensive reporting.
• Quality Assurance: The fee covers processing at NABL-accredited Apollo laboratories, ensuring the results meet stringent diagnostic standards required for rheumatological care.
• Location: Prices may differ slightly between cities due to regional operating costs and logistics.
• Service Type: Opting for home sample collection may slightly adjust the total cost due to convenience and travel charges.

To find the most accurate and current Scleroderma Diagnostic Panel price near me, please check the Apollo 24|7 app or website for real-time pricing specific to your location.

What is the Purpose of the Scleroderma Diagnostic Panel?

The primary purpose of this multi-marker panel is to provide a comprehensive serological profile to support the clinical diagnosis of Scleroderma and related conditions.

• Establish Diagnosis: To confirm the presence of Scleroderma when clinical symptoms (like Raynaud's phenomenon, skin changes, and joint issues) are present.
• Disease Classification: To help classify the type of Scleroderma (Limited vs. Diffuse). This is crucial, as the classification guides initial treatment intensity and monitoring schedules.
• Prognostic Assessment: Specific antibodies predict risk. For example, the presence of Anti-Scl-70 indicates a higher risk for severe complications like lung fibrosis, while Anti-Centromere suggests a higher risk for pulmonary hypertension.
• Differential Diagnosis: To help rule out or confirm overlap syndromes, such as Mixed Connective Tissue Disease (MCTD), which shares some symptoms with SSc.

Who Should Get the Scleroderma Diagnostic Panel Done?

This panel is typically ordered by a Rheumatologist or General Physician when a patient presents with clinical signs suggestive of Scleroderma or another related autoimmune disease.

You may be advised to take this test if:

• You exhibit Raynaud's phenomenon (episodes of reduced blood flow to the fingers and toes, causing them to turn white or blue), especially if it occurs along with other systemic symptoms.
• You have unexplained skin thickening or tightness, particularly on the hands, arms, face, or trunk.
• You have a positive or indeterminate ANA screen result, and the physician needs to identify the specific autoantibody to pinpoint the underlying condition.
• You experience symptoms of potential organ involvement, such as difficulty swallowing (oesophageal dysmotility), unexplained shortness of breath (suggesting lung fibrosis), or joint pain/stiffness.
• Your physician is attempting to confirm a diagnosis of CREST syndrome (Calcinosis, Raynaud's, Oesophageal dysmotility, Sclerodactyly, Telangiectasias), which is typically associated with Limited Scleroderma.

Components of Scleroderma Diagnostic Panel (ANA, U1 SM RNP, Centromere Abs, Scleroderma-70 IgG)

The Scleroderma Diagnostic Panel is a comprehensive autoimmune screening test that measures multiple antibodies associated with systemic sclerosis and related connective tissue diseases. It includes the following key components:

Scleroderma Diagnostic Panel (ANA, U1 SM RNP, Centromere Abs, Scleroderma-70 IgG):

• This combined panel detects autoantibodies that help diagnose and classify scleroderma (systemic sclerosis) and overlap syndromes.
• Antinuclear Antibodies (ANA): This serves as a vital initial screening test. A positive result and specific patterns (like Centromere or Homogeneous/Speckled) are strong indicators for Scleroderma or other connective tissue diseases (CTDs).
• Scleroderma-70 (Scl-70/Topoisomerase I) IgG: A highly specific marker for Diffuse Cutaneous Systemic Sclerosis (dcSSc), often associated with a higher risk of severe internal organ involvement, particularly interstitial lung disease (ILD) and scleroderma renal crisis.
• Centromere Antibodies IgG: A highly specific marker for Limited Cutaneous Systemic Sclerosis (lcSSc), often referred to as CREST syndrome. This antibody is linked to a better long-term prognosis for major organ disease but an increased risk of pulmonary hypertension.
• U1 SM RNP IgG: While not specific to Scleroderma alone, the presence of U1 RNP antibodies, often along with Scleroderma-specific markers, can suggest an Overlap Syndrome or Mixed Connective Tissue Disease (MCTD).

Understanding a Scleroderma Diagnostic Panel Report

The report for this panel will include results for multiple distinct markers. The key to interpretation lies in combining the results of the ANA screening with the results of the highly specific IgG antibodies.

Interpretation Note: A positive result for a specific antibody (Scl-70 or Centromere) carries a high predictive value for Scleroderma. The presence of either Scl-70 or Centromere usually defines the patient’s disease classification, regardless of other markers. The result must always be correlated with the patient's clinical presentation by a Rheumatologist.

Preparation and Procedure for the Scleroderma Diagnostic Panel

The Scleroderma Diagnostic Panel requires minimal preparation, ensuring the test can be easily performed in a timely manner when clinical urgency dictates.

How Is the Scleroderma Diagnostic Panel Performed?

A trained phlebotomist collects a small venous blood sample, usually from your arm. The serum is then separated and sent to the laboratory. The lab utilises specialised automated immunoassays (like ELISA, Immunoblot, or multiplex assays) to individually detect and measure the concentration (titer or index) of each autoantibody listed in the panel.

Is Fasting Needed Before the Test?

No, fasting is not required for the Scleroderma Diagnostic Panel. The presence of food or drink does not affect the measurement of autoantibodies in the blood.

What Is the Best Time of Day to Take the Test?

The test can be done at any time of day. Antibody levels are generally stable throughout the day.

Can Medications Affect the Test Results?

Certain medications, particularly high doses of systemic corticosteroids or immunosuppressive drugs, can potentially lower overall antibody levels. It is critical to inform your ordering physician about all medications, but do not stop any prescribed treatment unless instructed by your healthcare provider.

How Often Should the Test Be Conducted?

This panel is primarily a diagnostic test, usually performed once to establish the initial diagnosis and classification. It is not typically used for routine monitoring, as the autoantibody status generally remains stable over the course of the disease. Repeat testing might be considered in very rare cases of an initial equivocal result or clinical suspicion of a change in diagnosis.

Booking the Scleroderma Diagnostic Panel Online & Checking Reports

Apollo 24|7 streamlines the process of scheduling this specialised diagnostic panel and accessing your results.

A. What are the Steps to Schedule the Test on Apollo 24|7?

• Visit the Apollo 24|7 website or mobile application and search for Scleroderma Diagnostic Panel.
• Review the latest test price for your city and click the ‘Book Now’ button.
• Select your preferred date and a convenient time slot for home sample collection.
• Complete the secure online payment. You will receive immediate confirmation and preparation details.

B. How Do I Access My Test Results Online on Apollo 24|7?

• 
  Log in to your Apollo 24|7 account using your registered phone number or email ID.
• Go to the ‘Health Records’ or ‘My Reports’ section on your dashboard.
• Click on the test name to view your detailed, NABL-certified report as soon as it is available.
• You can easily view the report online or download it in PDF format to share instantly with your physician.

Conclusion

The Scleroderma Diagnostic Panel represents a powerful tool in rheumatology. By simultaneously screening for ANA and pinpointing the presence of key antibodies like Scl-70 and Centromere, it not only confirms a diagnosis of Scleroderma but, most critically, helps physicians predict the patient's disease course and potential organ involvement. This enables timely and targeted therapeutic intervention, improving patient outcomes. Accessing this complex panel through accredited platforms like Apollo 24|7 ensures the diagnostic accuracy needed for managing this challenging autoimmune condition.